Corbus Pharmaceuticals Holdings (CRBP) Assets Average (2014 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Assets Average of $138.9 million for Q4 2025, down 13.23% year-over-year from $160.0 million in Q4 2024, and up 18.38% quarter-over-quarter from $117.3 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Assets Average (2014 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Assets Average history runs 12 years deep, the most recent figure standing at $138.9 million for Q4 2025.
- In Q4 2025, Assets Average fell 13.23% year-over-year to $138.9 million; the TTM figure through Dec 2025 stood at $138.9 million (down 13.23% YoY), while the FY2025 annual figure was $162.0 million, up 75.98% from the prior year.
- Assets Average for Q4 2025 stood at $138.9 million, up from $117.3 million in the prior quarter.
- The five-year high for Assets Average was $160.0 million in Q4 2024, with the low at $32.3 million in Q4 2023.
- The 5-year median for Assets Average is $115.5 million (2021), against an average of $103.7 million.
- The sharpest annual moves came in 2023 and 2024: Assets Average tumbled 53.94% in 2023, then soared 395.78% in 2024.
- Corbus Pharmaceuticals Holdings' Assets Average stood at $113.7 million in 2021, then slumped by 38.35% to $70.1 million in 2022, then plunged by 53.94% to $32.3 million in 2023, then jumped by 395.78% to $160.0 million in 2024, then declined by 13.23% to $138.9 million in 2025.
- Business Quant data shows CRBP's Assets Average at $138.9 million in Q4 2025, $117.3 million in Q3 2025, and $132.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | 138.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 138.85 Mn |
| Sep 30, 2025 | 117.30 Mn |
| Jun 30, 2025 | 132.51 Mn |
| Mar 31, 2025 | 147.91 Mn |
| Dec 31, 2024 | 160.03 Mn |
| Sep 30, 2024 | 158.08 Mn |
| Jun 30, 2024 | 138.86 Mn |
| Mar 31, 2024 | 77.01 Mn |
| Dec 31, 2023 | 32.28 Mn |
| Sep 30, 2023 | 40.00 Mn |
| Jun 30, 2023 | 47.68 Mn |
| Mar 31, 2023 | 58.98 Mn |
| Dec 31, 2022 | 70.07 Mn |
| Sep 30, 2022 | 77.95 Mn |
| Jun 30, 2022 | 88.87 Mn |
| Mar 31, 2022 | 101.70 Mn |
| Dec 31, 2021 | 113.65 Mn |
| Sep 30, 2021 | 120.09 Mn |
| Jun 30, 2021 | 130.38 Mn |
| Mar 31, 2021 | 121.22 Mn |